Humanin Peptide Guide: Dosage, Mitochondrial Protection & Longevity Explained
Humanin
Humanin is a mitochondrial-derived peptide first identified for its cytoprotective activity in cellular models. Preclinical research has investigated Humanin and its analogs in neuroprotection, metabolic signaling, cardiovascular function, cellular stress, and aging-related pathways. Human observational studies have also measured naturally occurring Humanin levels, but exogenous Humanin has not been validated as a therapeutic treatment in human clinical trials.
How It Works
Mitochondrial-Derived Signaling → Stress-Response Pathways → Anti-Apoptotic Signaling Research
Humanin is a mitochondrial-derived peptide associated with cellular stress-response signaling. Preclinical research suggests interactions with anti-apoptotic, metabolic, inflammatory, and neuroprotective pathways. These mechanisms have primarily been demonstrated in cellular and animal models and should not be interpreted as established longevity or therapeutic effects in humans.
Humanin Research-Use Framework
Important Evidence Distinction:
Humanin does not currently have an established human dosing protocol. The example amounts shown below reflect research-use dosing frameworks discussed outside clinical trials and should not be confused with doses established through human safety, dose-finding, or efficacy studies.
Humanin does not currently have an established human dosing protocol. The example amounts shown below reflect research-use dosing frameworks discussed outside clinical trials and should not be confused with doses established through human safety, dose-finding, or efficacy studies.
5 mg Vial + 2.0 mL BAC Water → 2.5 mg/mL → 1 Unit = 25 mcg
Example Research-Use Setup
Vial
5 mg
Water
2.0 mL bacteriostatic water
Concentration
2.5 mg/mL
Conversion
1 unit = 25 mcg
Example Starting Range
Starting
Dose
100 mcg daily
Units
4 units
Volume
0.04 mL
Commonly Discussed Research-Use Range
Research Use
Dose
200–300 mcg daily
Units
8–12 units
Volume
0.08–0.12 mL
Higher Research-Use Reference
Higher Range
Dose
500 mcg daily
Units
20 units
Volume
0.20 mL
Simple Approach:
Humanin is commonly discussed in conservative research-use frameworks, but no human dose-finding studies have established an optimal starting range or dose-escalation schedule. Higher amounts should not automatically be assumed to produce greater cellular or longevity-related effects.
Humanin is commonly discussed in conservative research-use frameworks, but no human dose-finding studies have established an optimal starting range or dose-escalation schedule. Higher amounts should not automatically be assumed to produce greater cellular or longevity-related effects.
What the Research Actually Shows
Published Evidence Context
Humanin research includes extensive cellular and animal studies, but a standardized therapeutic human dosing regimen has not been established.
Human studies primarily measure naturally occurring Humanin levels and examine associations with aging, metabolic health, cardiovascular disease, and other conditions.
Preclinical treatment studies have used different Humanin compounds, doses, routes, and animal models rather than one standardized protocol.
Much of the therapeutic animal literature uses HNG (S14G-Humanin), a modified Humanin analog, rather than native Humanin.
Published human research does not establish 100 mcg, 200–300 mcg, or 500 mcg daily as validated therapeutic doses.
Why this matters:
Research showing associations between naturally occurring Humanin levels and human health does not demonstrate that administering synthetic Humanin produces the same effects. Animal dosing also cannot be directly converted into a validated human protocol without human pharmacokinetic, safety, and dose-finding studies.
Research showing associations between naturally occurring Humanin levels and human health does not demonstrate that administering synthetic Humanin produces the same effects. Animal dosing also cannot be directly converted into a validated human protocol without human pharmacokinetic, safety, and dose-finding studies.
How to Use Humanin (Cycle, Timing & Injection)
Example Research-Use Structure
Example Frequency
Once daily
Research-Use Route Shown
Subcutaneous
Example Cycle
2–4 weeks
Established Human Schedule
None established
Timing
No clinically established morning or evening administration time exists for Humanin.
Human pharmacokinetic studies have not established an optimal dosing interval or time of day.
Once-daily administration shown on this page represents an example research-use framework rather than a validated human schedule.
Route & Injection Sites
Subcutaneous administration is commonly discussed in research-use protocols but is not an established clinical Humanin treatment route.
Common subcutaneous injection areas include the abdomen, thigh, and upper arm.
Rotating injection sites can help reduce repeated irritation in the same area.
Areas of Research Interest
Mitochondrial-derived peptide signaling
Cellular stress-response and survival pathways
Neuroprotection in cellular and animal models
Metabolic and insulin-signaling research
Cardiovascular and age-related biology
Important Context:
The once-daily, subcutaneous, 2–4 week structure shown here has not been established through controlled human Humanin trials. It represents a research-use framework and should not be interpreted as a clinically validated route, frequency, cycle length, or timing schedule.
The once-daily, subcutaneous, 2–4 week structure shown here has not been established through controlled human Humanin trials. It represents a research-use framework and should not be interpreted as a clinically validated route, frequency, cycle length, or timing schedule.
Research-Use vs Published Evidence
Research-Use Context
Commonly Discussed Range
100–300 mcg daily
Higher Research-Use Reference
Up to 500 mcg daily
Validated Human Dose
None established
Published Evidence
Human Evidence
Primarily observational studies of naturally occurring Humanin
Therapeutic Evidence
Primarily cellular and animal research
Research Areas
Neuroprotection, metabolism, cellular stress, cardiovascular and aging biology
Human Clinical Protocol
Not established
Important distinction:
Human studies measuring naturally occurring Humanin levels do not establish that administering synthetic Humanin produces the same effects. The 100–500 mcg amounts discussed in research-use settings have not been validated through human dose-finding, safety, or efficacy trials.
Human studies measuring naturally occurring Humanin levels do not establish that administering synthetic Humanin produces the same effects. The 100–500 mcg amounts discussed in research-use settings have not been validated through human dose-finding, safety, or efficacy trials.
Reconstitution & Dose Conversion
Reconstitution Setup
Vial
5 mg
Water
2.0 mL bacteriostatic water
Concentration
2.5 mg/mL
Conversion
1 unit = 25 mcg
Conversion Reference
4 units = 100 mcg
8 units = 200 mcg
12 units = 300 mcg
20 units = 500 mcg
Reconstitution Steps
Draw 2.0 mL bacteriostatic water
Add the water slowly down the inside wall of the vial
Gently swirl or roll the vial rather than shaking
Allow the contents to dissolve completely before use
Refrigerate after reconstitution
Research Context:
These values are mathematical concentration and syringe conversions. They do not establish an appropriate or clinically validated Humanin dose.
These values are mathematical concentration and syringe conversions. They do not establish an appropriate or clinically validated Humanin dose.
Storage & Shelf Life
Storage & Shelf Life
Lyophilized (unmixed)
Refrigerated (2–8°C): ~12–24 months
Frozen (−20°C): up to ~2–3 years
Store sealed, dry, and protected from light
Reconstituted (mixed)
Refrigerated (2–8°C): about 30 days typical use window
Do not freeze after mixing
Avoid repeated temperature changes
Best Practice
Handling
Keep the vial cold, protected from light, and minimize unnecessary handling.
Visual Check
If the solution becomes cloudy, discolored, or contains visible particles, it is safer not to continue using it.
Time Between Cycles
Research-Use Period → Reassess → Break if Cycling → Repeat if Appropriate
Research-Use Cycle Framework
Example Cycle
2–4 weeks
Commonly Discussed Break
2–4 weeks
Required Off-Period
Not established
Validated Human Cycle
None established
Why reassess?
The 2–4 week cycle and 2–4 week break shown here represent a research-use framework rather than a clinically established Humanin schedule. Human studies have not determined an optimal treatment duration, required off-period, or repeat-cycle frequency for exogenous Humanin.
The 2–4 week cycle and 2–4 week break shown here represent a research-use framework rather than a clinically established Humanin schedule. Human studies have not determined an optimal treatment duration, required off-period, or repeat-cycle frequency for exogenous Humanin.
Research-Use Structure
Example Framework
2–4 weeks followed by reassessment
A 2–4 week break is commonly discussed in research-use frameworks but has not been clinically validated.
Published evidence does not establish that Humanin requires cycling rather than continuous administration.
Research does not establish a specific interval at which Humanin should be repeated.
Reasons to Reassess
The defined research-use period has ended
No meaningful change is being observed for the research goal
New or unexpected effects occur during the research period
Continued use no longer has a clearly defined research purpose
Important Context:
Humanin does not currently have a validated human therapeutic dosing, cycling, or washout protocol. The timing shown above should therefore be understood as a research-use framework rather than an evidence-based requirement.
Humanin does not currently have a validated human therapeutic dosing, cycling, or washout protocol. The timing shown above should therefore be understood as a research-use framework rather than an evidence-based requirement.
Monitoring During Use
Energy levels
Cognitive clarity
Recovery and resilience
Overall well-being
Benefits
Preclinical studies support a role for Humanin in cellular stress-response and survival signaling
Animal and cellular studies have investigated neuroprotective effects
Preclinical research has investigated metabolic, insulin-signaling, and cardiovascular effects
Human observational studies have found associations between endogenous Humanin levels and aging or metabolic health
Therapeutic anti-aging, neuroprotective, metabolic, or longevity benefits from administering Humanin have not been established in humans
Potential Side Effects
A human adverse-effect profile has not been established
Human pharmacokinetic and dose-escalation safety data are lacking
Long-term safety of exogenous Humanin or HNG administration in humans is unknown
Safety findings from animal studies should not be assumed to predict human tolerability
Important Notes
Humanin is a mitochondrial-derived peptide with extensive preclinical research but no established therapeutic human dosing protocol.
Human observational studies measuring naturally occurring Humanin should not be confused with trials administering synthetic Humanin.
Humanin and HNG / S14G-Humanin are different research compounds and should not be treated as dose-equivalent.
Combining Humanin with SS-31, MOTS-c, or other mitochondrial compounds has not been validated as a specific human clinical protocol.
Long-term human safety, pharmacokinetics, effective dose, and optimal treatment duration remain unknown.
Important Disclaimer
Humanin is an investigational peptide and is not FDA-approved. This content is for educational purposes only.
Research & References
Primary Research
- Hashimoto Y, Niikura T, Tajima H, et al. A Rescue Factor Abolishing Neuronal Cell Death by a Wide Spectrum of Familial Alzheimer's Disease Genes and Aβ. Proceedings of the National Academy of Sciences (PNAS). 2001.
- Lee C, Yen K, Cohen P. Humanin: A Harbinger of Mitochondrial-Derived Peptides? Trends in Endocrinology & Metabolism. 2013.
- Hazafa A, Batool A, Ahmad S, et al. Humanin: A Mitochondrial-Derived Peptide in the Treatment of Apoptosis-Related Diseases. Life Sciences. 2021.
Reviews & Supporting Research
- Rochette L, Meloux A, Zeller M, et al. Role of Humanin, a Mitochondrial-Derived Peptide, in Cardiovascular Disorders. Archives of Cardiovascular Diseases. 2020.
- Karachaliou CE, Livaniou E. Neuroprotective Action of Humanin and Humanin Analogues: Research Findings and Perspectives. Biology (Basel). 2023.
Research Note: Humanin's biological effects are well characterized in laboratory and animal models, but human clinical dosing research remains limited. Self-administration protocols described on this page extrapolate from preclinical research and compounding-community practice rather than from validated human dosing trials.
Comments
Post a Comment